Esperion Therapeutics (ESPR) Common Equity (2012 - 2026)

Esperion Therapeutics has reported Common Equity for 15 years, with the latest figure at -$307.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 27.75% year-over-year to -$307.9 million; the trailing twelve-month figure through Mar 2026 stood at -$307.9 million (up 27.75% YoY), and the FY2025 full-year result was -$302.0 million, up 22.32% from the prior year.
• Common Equity for Q1 2026 stood at -$307.9 million, down from -$302.0 million in the prior quarter.
• The five-year high for Common Equity was -$249.0 million in Q1 2022, with the low at -$455.0 million in Q4 2023.
• Historically, Common Equity has averaged -$355.5 million across 5 years, with a median of -$344.2 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity slumped 64.4% — and 2026, when it gained 27.75%.
• Esperion Therapeutics' Common Equity stood at -$323.8 million in 2022, then slumped by 40.53% to -$455.0 million in 2023, then increased by 14.57% to -$388.7 million in 2024, then grew by 22.32% to -$302.0 million in 2025, then declined by 1.98% to -$307.9 million in 2026.
• The last three Common Equity figures came in at -$307.9 million (Q1 2026), -$302.0 million (Q4 2025), and -$451.4 million (Q3 2025), per Business Quant data.